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Abstract
Introduction. Renal involvement in systemic lupus erythematosus (SLE) is associated with production of anti-
bodies to double stranded DNA, deposition of immune complexes and organ damage. These processes have 
been linked with abnormalities in B- and T-cell memory compartments. The aim of the study was to analyze 
subsets of peripheral memory B-cells and T-cells in lupus nephritis (LN) patients. 
Material and methods. We used multicolor flow cytometry to analyze major memory subsets of peripheral blood 
B-cells (defined by CD27, IgD and CD21) and T-cells (CD45RA, CD45RO, CCR7) in 32 patients with active 
or inactive LN, and 23 control subjects.
Results. Lupus nephritis patients were characterized by increased percentage of immature/early-transitional 
B-cells (CD27-IgD+CD21-), higher frequency of activated switched memory (SM, CD27+IgD-CD21-) and 
exhausted memory B-cells (CD27-IgD-), and decrease in non-switched memory (NSM, CD27+IgD+) B-cells. 
CD21low subsets (immature and activated B-cells) were particularly expanded in patients with active disease. 
In both groups of LN patients we observed decline in the absolute count of NSM B-cells. It was paralleled by 
lymphopenia in naïve CD4+ T-cell compartment and increase in the frequency of effector memory T-cells, and 
these changes were more pronounced in active LN.
Conclusions. B-cell memory compartment in LN is deficient in NSM cells and during active disease it is further 
skewed towards SM and exhausted memory phenotypes, most likely as a cause of chronic antigenic stimulation. 
Parallel changes in T-helper cell subsets suggest a similar mechanism of SLE-related lymphopenia for both B-cell 
and T-cell compartment. (Folia Histochem Cytobiol. 2016, Vol. 54, No. 1, 32–41)
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Introduction
Systemic lupus erythematosus (SLE) is a complex 
autoimmune disorder with B-cell hyper-reactivity, im-
mune complex deposition, and organ damage. Lupus 
nephritis (LN) develops in ~50% SLE patients, repre-
senting the main cause of morbidity and mortality [1, 2]. 
The significance of self-reacting B-cells in the patho-
genesis of LN is supported by a strong causal link 
between autoantibodies against double stranded 
DNA (dsDNA) and renal involvement [3, 4]. Addi-
tionally, rise in the titer of anti-dsDNA antibodies 
occurs years before the clinical onset of proliferative 
LN [5, 6]. It has been suggested that autoimmune 
inflammation results from repeated stimulation of 
autoreactive memory T- and B-cells, and subsequent 
effector responses mediated in part by circulating 
autoantibodies. 
During primary immune response to T-cell de-
pendent (TD) antigens naïve B-cells receive signals 
from T-helper cells and proliferate rapidly forming 
germinal centers (GC) in lymphoid tissues. Many of 
responding B-cells undergo somatic hypermutation 
and class switching [7]. Memory B-cells generated 
during GC reaction can be recognized by surface 
expression of CD27, and are classified as switched 
memory cells (SM; CD27+IgD-), or non-switched 
(i.e. IgM+) memory cells (NSM; CD27+IgD+) [8]. 
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During secondary antigen exposure SM B-cells prolif-
erate rapidly and differentiate into antibody secreting 
cells, while NSM cells are able to reinitiate GC reac-
tion and replenish SM fraction [9, 10]. Because B-cell 
response to nuclear auto-antigens requires T-cell help, 
formation of pathogenic autoantibodies in SLE (e.g. 
anti-dsDNA) follows the same rules [11]. As a con-
sequence, in all SLE patients a pool of autoreactive 
memory B- and T-cells is steadily generated. It has 
been hypothesized that continuous presence to au-
toantigens favors differentiation of effector memory 
(EM) T-cells, which mount a pathogenic inflamma-
tory response upon re-exposure to self-antigens [12]. 
Similarly to other memory cells, they are long-lived 
and difficult to eliminate, thus pose a considerable 
therapeutic challenge [13]. 
Lymphocyte phenotyping in SLE patients re-
vealed expansion of CD27+ memory B-cells with 
parallel decline in naïve compartment, but little is 
known if they are intrinsic or develop secondarily to 
disease-related inflammation [14–16]. Interestingly, 
memory B-cells in lupus patients often display ‘double 
negative’ (i.e. CD27-IgD-) phenotype and correlate 
with renal involvement [17, 18]. Additionally, several 
groups reported on marked decline in the frequency 
of CD27+IgD+ B-cells (NSM) mostly in patients with 
active disease [18–20]. B-cell lymphopenia is another 
typical feature of SLE, but less is known if it affects all 
B-cell subsets, and whether it is associated with similar 
abnormalities in T-cell compartment. Therefore in 
this study we aimed to analyze subsets of circulating 
B-cells in LN patients, in search for potential markers 
associated with disease activity. Additionally, we com-
pared changes in B-cell and T-cell subsets depending 
on SLE-related lymphopenia. 
Material and methods
Characteristics of the patients. Blood samples were taken 
from 34 systemic lupus erythematosus (SLE) patients with re-
nal involvement, and 23 control subjects (apparently healthy, 
with negative laboratory tests for antinuclear and antiphos-
pholipid autoantibodies). SLE was diagnosed based on up-
dated criteria of the American College of Rheumatology [21]. 
LN was confirmed by renal biopsy and classified according 
to International Society of Nephrology/Renal Pathology 
Society (ISN/RPS) criteria [22] as class II (3%), III (15%), 
IV (56%) or V (8%). In 6 patients (18%) LN was diagnosed 
based on overt renal symptoms (proteinuria, active urinary 
sediment) during lupus flare. We enrolled 16 LN patients with 
disease exacerbation (active-LN, SLE Disease Activity Index 
[SLEDAI] > 6, urine protein > 1 g/day or > 2-fold increase 
with active urinary sediment) and 18 patients in remission 
(inactive-LN, SLEDAI £ 6, urine protein < 1 and normal 
urinary sediment) [23]. All but one active-LN patients had 
additional SLE symptoms: hematologic (88%, mostly lym-
phopenia), joint symptoms (50%), skin lesions (50%), and 
pleuritis (19%). LN patients were not treated with biological 
agents targeting B-cells (e.g. rituximab). Additionally, they 
were not treated with cyclophosphamide in the preceding 
6 months. The clinical and laboratory characteristics of LN 
patients are summarized in Table 1. The study was approved 
by the Ethics Committee of the Jagiellonian University and 
informed written consent was obtained from all participants.
Flow cytometry. Aliquots of EDTA anticoagulated blood 
were stained with a mixture of monoclonal antibodies (all 
from BD Biosciences, Franklin Lakes, NJ, USA) for de-
tection of CD19+ B-cell (anti-CD45, CD3, CD19, CD21, 
CD27, IgD; gating strategy shown in Figures 1A, B) and 
T-cell memory subpopulations (anti-CD45, CD3, CD4, 
CD8, CD45RA, CD45RO, CCR7). Samples were fixed with 
FACS lysing solution (BD Biosciences), washed and ana-
lyzed in FACS Canto II flow cytometer (BD Biosciences). 
Based on differential expression of surface markers 
the following B-cell subsets were identified: immature/ 
/early-transitional (I/T, CD27-IgD+CD21low), late-transi-
tional/naïve (CD27-IgD+CD21+), non-switched memory 
(NSM, CD27+IgD+), resting class-switched memory (SM, 
CD27+IgD-CD21+), activated SM (CD27+IgD-CD21low), 
and double-negative (CD27-IgD-) exhausted memory (ExM) 
as summarized in Figure 1C [8, 16, 23, 25]. Using T-cell 
panel we identified four subsets within CD4+ or CD8+ 
gate: naïve (CD45RA+CD45RO-CCR7+), central mem-
ory (TCM, CD45RA-CD45RO+CCR7+), effector memory 
(TEM, CD45RA-CD45RO+CCR7-), and effector memory 
CD45RA+ (TEMRA, CD45RA+CD45RO-CCR7-) [26, 27].
Statistical methods. Statistical analysis was performed 
using GraphPad Prism 5.0 (GraphPad Software, Inc., San 
Diego, CA, USA). Data is presented as medians and 25–75 
quartile ranges if not otherwise stated. Differences between 
two groups were determined by a Mann-Whitney U test. 
Differences between at least three groups were determined 
by ANOVA or Kruskal-Wallis test if justified. Spearman’s 
rank sum test was used to analyze correlation coefficients. 
P value < 0.05 was considered significant.
Results
Decreased frequency of non-switched memory  
B-cells and signs of B-cell exhaustion in LN
The phenotypic characteristics of the analyzed B-cell 
subsets have been shown in Figure 1C. There was 
a large variability in the percentage of CD19+ B-cells 
in LN patients, with no difference in comparison with 
control group. B-cell counts were significantly lower 
in LN patients both with active and inactive disease 
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(Figure 1D). LN patients showed high variability 
in the distribution of main B-cell subsets, which 
was more evident in patients with the active disease 
(Figure 1E). The percentage of early-transitional 
B-cells (CD27-IgD+CD21low) was increased in the 
active LN (median 6.5% of CD19+) as compared 
with inactive LN (3.0%, P < 0.05) and control (2.1%, 
P < 0.01) groups (Figure 1F). In all patients with 
active LN, and in majority (n = 15, 83%) of patients 
with inactive disease, we observed a marked decrease 
(median 2.4% and 2.3%, respectively) in the percent-
age of NSM B-cells (Figure 1E, F) as compared with 
control subjects (13.4%). This was a characteristic 
feature of B-cell memory compartment, distinctive to 
SLE (Figure 1G). Additionally, we observed increased 
frequency of activated SM cells in active LN (median 
12.6%) as compared with other groups (inactive LN 
— 6.0%, P < 0.05, control — 2.5%, P < 0,01). 
Moreover, B-cell compartment in LN patients had 
signs of memory exhaustion, as evidenced (Figure 1E, F) 
by increased percentage of double negative (CD27- 
-IgD-) CD19+ B-cells (median 6.8% in active- and 9.9% 
in inactive-LN vs. 2.4% in control group, P < 0.01). 
Next, we compared absolute counts of B-cells in or-
der to identify changes associated with SLE-induced 
lymphopenia. As shown in Figure 1H, there was 
a strong (> 10-fold) decrease in the number of NSM 
B-cells in LN patients (independently of the activity 
of the disease) as compared with control group, but 
we also found a significant, though less pronounced 
decrease in the count of naïve and resting SM B-cells. 
Subsets of CD21low B-cells correlate with LN activity
Overall, there was a strong association of B-cells with 
decreased expression of CD21 (comprised of ear-
ly-transitional and activated/exhausted B-cells) with 
the activity of the disease (Figure 2A). In particular, 
we showed a correlation (Figure 2B, C) between the 
percentage of immature/early-transitional B-cells 
and various markers of SLE activity, e.g. SLEDAI 
Table 1. Characteristics of the subjects studied
Active LN (n = 16) Inactive LN (n = 18) Control group (n = 23)
Age (years) 35 [30–47] 35 [29–50] 34 [27–41]
Sex (Females, %) 12 (75%) 15 (83%) 18 (78%)
SLE duration (years) 10 [3–14.5] 9.5 [4–15] n.a.
Symptoms (in history) – – n.a.
Skin 15 (94%) 14 [78%]
Joints 16 (100%) 15 [83%]
Pleuropericarditis 6 (38%) 8 [44%]
Neurologic 1 (6%) 2 [11%]
Hematologic 16 (100%) 16 [89%]
LN class II/III/IV/V(unknown)1 1/2/9/2(2) 0/3/10/1(4) n.a.
SLEDAI (score) 21.5 [14–24]## 2 [0–4] n.a.
ANA (titer) 10240 [5120–20480] 5120 [2240–10240] none
Anti-dsDNA (titer) 480 [160–2560]## 40 [< 10–160] none
Proteinuria (g/day) 2.4 [1.7–5.2]## 0.1 [0.06–0.39] n.a.
Creatinine (serum, μmol/L) 69.5 [65.2–91.7] 66 [60.2–80.5] 71 [65–79]
C3c (mg/dL) 0.545 [0.44–0.785]**,## 1.035 [0.790–1.185]* 1.15 [0.963–1.41]
CRP (mg/L) 17.1 [9.1–25.8]**,## 1.7 [0.6–7.7]* 0.7 [0.3–2.8]
WBC (•103/uL) 5.2 [4.1–8.1] 6.4 [4.4–8.8] 6.3 [5.7–7.9]
Lymphocytes (•103/uL) 0.67 [0.37–1.26]** 0.89 [0.65–1.38]** 1.82 [1.61–2.21]
Current systemic GCS (mg/d) 8 [4–16]# 4 [0–4] none
Cumulative CTX dose (g) 0 [0–8.6]## 9.5 [6.1–26.2] n.a.
1According to International Society of Nephrology/Renal Pathology Society criteria [22]. Data are presented as medians [25–75 quartiles]. *, **P < 0.05 
and *P < 0.01, respectively, in comparison with control group; #, ##P < 0.05 and P < 0.01, respectively, in comparison with Inactive LN.  
Abbreviations: ANA — anti-nuclear antibodies; C3c — complement component C3c; CRP — C-reactive protein; CTX — cyclophosphamide;  
GCS — glucocorticoids (recounted for methylprednisolone); LN — lupus nephritis; SLEDAI — SLE disease activity index; WBC — white blood cells
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Figure 1. Subsets of memory B-cells in systemic lupus erythematosus (SLE) patients and control subjects. A. Flow cyto-
metry (FC) gating strategy used to identify major subsets of CD19+ B-cells (details in the methods section, abbreviations 
explained in C). Dot-plots represent FC data of a control individual (K20); B. Similar gating strategy applied to FC data 
of lupus nephritis (LN) patient (P04); C. Diagram summarizing main subtypes of circulating CD19+ B-cells identified on 
the basis of the expression of CD21, CD27 and IgD; D. Percentage and counts of peripheral blood CD19+ B-cells in all 
studied groups. Horizontal bars represent medians; E. Percentages of different CD19+ B-cell subsets shown separately 
for each individual (data for CD21low NSM cells were also included)
B
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(R = 0.48), dsDNA (R = 0.61) and complement com-
ponents (e.g. C4, R = –0.48). Additionally, percentage 
of activated SM B-cells showed weak association 
with SLEDAI score (R = 0.37) and peripheral blood 
lymphocyte count (R = –0.35). As expected, absolute 
counts of naïve, NSM and resting SM B-cells also 
correlated with clinical markers of the disease (not 
shown). Interestingly, activated SM B-cells (but not 
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Figure 1. (cont.) Subsets of memory B-cells in SLE patients and control subjects. F. Differences in the percentage values of  
B-cells between all studied groups. Horizontal bars represent medians. *P < 0.05, **P < 0.01; G. ROC curves of the prediction 
of a given disease phenotype based on NSM (% of CD19+) data. Individual AUC (area under the curve) values are plotted 
next to each representative data-set; H. Fold changes in the number of analyzed B-cell subsets (RC — relative to control group, 
e.g. value 0.1 means 10-fold decrease, data presented as means and 95% CI). Naïve, NSM and resting-SM B-cells were signifi-
cantly decreased (**P < 0.01) in both active- and inactive-LN patients as compared with controls
other B-cell types) correlated weakly with daily urine 
protein excretion (R = 0.36) and urine sediment 
erythrocytes (R = 0.51). Percentage of memory B-cell 
subsets was comparable in LN-patients stratified 
based on renal biopsy status (data not shown).
Increased percentage of effector memory  
T-cells in LN
The decrease in absolute number of T-cells was com-
parable in active- and inactive-LN (median 514 and 
700 cells/μL, respectively, vs. 1388 in control subjects, 
P < 0.01) and affected mostly CD4+ T-cells (237 and 
409 cells/μL in LN groups vs. 923 in controls, P < 0.01) 
resulting in lower percentage of CD4+ T-cell in LN 
(median 37% of total lymphocytes in all LN patients 
vs. 47% in controls) and decreased CD4/CD8 ratio 
(1.01 and 1.67 in active- and inactive-LN vs. 2.37 in 
controls, P < 0.01). Additional staining for CD45RA, 
CD45RO and CCR7 (Figure 3A) allowed for identifi-
cation of naïve and memory T-cell subsets (Figure 3B). 
The main feature of T-cell compartment in LN was 
a significant decrease in the percentage of naïve 
T-helper cells (36.8% in LN vs. 48.0% in control 
group, P < 0.05) and increase in the percentage of 
TEM subset (29.7% vs. 14.5%, respectively, P < 0.01), 
with no difference between active and inactive disease 
(Figure 3C). The frequency of CD8+ T-cell subsets 
did not change considerably in LN (Figure 3C). Fur-
ther analysis showed significant decrease in the abso-
lute count of naïve and TCM cells (primarily CD4+) in 
LN as compared with control subjects, which was more 
prominent in the active disease (Figure 3D). Compar-
ison of B-cell and T-cell memory fractions revealed 
a weak correlation of the percentage of CD4+ TEM 
with both NSM (r = –0.42) and ExM B-cells (r = 0.48). 
Not surprisingly, there was a considerable correlation 
between the magnitude in the decrease of absolute 
counts of CD4+ T and B fractions, which was most 
prominent in case of naïve CD4+ and NSM B-cells 
(Figure 3F).
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Figure 2. Association of B-cell subsets with clinical and laboratory parameters of lupus nephritis (LN). A. Percentage of 
CD21low B-cells in the studied groups. **P < 0.01; B. Correlation matrix showing significant (P < 0.05, bold) associations 
between the main subsets of B-cells (abbreviations explained in Fig. 1C) and selected markers of active SLE (data from 
the whole SLE group). CRP — C-reactive protein, C3c — complement component 3Cc, C4 — complement component 
C4, PBL — peripheral blood lymphocytes (count), CTX — cyclophosphamide (cumulative dose); C. Scatter-plots showing 
the correlations of the percentage of immature/transitional B-cells with serum levels of C3c and SLEDAI score
A B
C
Discussion
Earlier studies showed specific changes in B-cell 
compartment in SLE, though data on the association 
between various memory B-cells and disease activity 
are inconsistent [18, 28, 29]. To address this point we 
quantified different subsets of B-cells in patients with 
inactive LN and during disease exacerbations, and 
also checked if they are paralleled by similar changes 
within T-cell memory compartment. We defined main 
subsets of B-cells based on multicolor flow cytometry 
panel, including staining for CD27 (memory marker), 
surface-IgD and CD21 (complement receptor CR2, 
a component of BCR co-receptor complex), which 
allowed to distinguish switched and non-switched 
memory B-cells and additionally CD21low immature 
and activated B-cells.
Decreased frequency of NSM B-cells was the 
most prominent feature of LN in the current study. 
This alteration was observed in all LN patients with 
disease exacerbation and in a majority (83%) of pa-
tients in remission. Our data is in line with previous 
reports showing deficiency in CD27+IgD+ cells in 
SLE [18, 19], though in contrast to earlier study [18], 
we did not see any association of B-cell NSM percent-
age with disease activity status. The subset of NSM 
B-cells has been implicated in immune responses 
against T-cell independent antigens, however re-
cent studies confirmed their role as a long-lasting 
memory to T-cell dependent antigens involved in 
reconstitution of switched memory pool upon antigen 
restimulation [10]. Changes in NSM fraction were 
accompanied by increased percentage of immature/ 
/early-transitional B-cells and activated SM cells, both 
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Figure 3. Memory T-cell subsets in systemic lupus erythematosus (SLE). A. Flow cytometry dot-plots (whole blood gated 
on CD4+ or CD8+ T-cells) showing major subsets of memory T-cells. CM — central memory, EM — effector memory, 
EMRA — effector memory CD45RA+; B. Simplified diagram showing the main stages of differentiation of memory  
T-cells and their candidate surface markers (based on [16, 22]); C. Percentages (within CD4+ [left] or CD8+ [right] T-cells) 
of memory subsets in control subjects and lupus nephritis (LN) patients. Horizontal bars represent mean values. *P < 0.05, 
**P < 0.01; D. Graph showing the relative decrease in the absolute counts of CD8+ and CD4+ memory subsets in LN 
patients as compared with control group (RC — relative to controls). Whiskers represent 95% CI. *P < 0.01 in comparison 
with controls. #P < 0.05 between active and inactive LN; E. Correlation matrix shows Pearson r coefficients in comparisons 
of major memory subsets of CD19+ B-cells (abbreviations explained in the Fig. 1C) and CD4+ T-cells in LN group.  
Significant (P < 0.05) associations are marked in bold font; F. Correlation between fold decrease (in comparison with 
mean value in the control group, RC — relative to control) in NSM B-cells and naïve CD4+ T-cells in LN patients
A B
C
D
E F
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subsets defined as CD21low. During development of 
humoral response the loss of CD21 expression in 
CD27+ memory B-cells occurs during their activation 
and differentiation towards antibody secreting cells 
[8, 16, 23]. Nevertheless, systemic accumulation of 
B-cells with CD27+CD21low phenotype, e.g. during 
chronic viral infections, is also considered as a sign of 
aberrant B-cell activation and dysfunction within the 
memory compartment [21, 30]. In this study we ob-
served very similar B-cell changes in LN patients. The 
fraction of activated SM B-cells (CD27+CD21low) 
was ~3-fold higher in patients with active LN as 
compared with control group. In line with previous 
reports [17, 18, 29], we also observed increased fre-
quency of double negative (i.e. CD27-IgD-) B-cells 
in patients with LN. This fraction represents class-
-switched memory cells that lost CD27 expression, 
which are also markedly expanded during chronic in-
fections, and resemble tissue-like exhausted memory 
B-cells [23, 32]. These results suggest altogether that 
reduction in NSM B-cells is most likely a consequence 
of facilitated class switch of IgM+ memory cells and 
further differentiation towards SM-activated and 
exhausted memory phenotypes. This was further con-
firmed by analysis of absolute counts of B-cells. As it 
turned out, SLE related lymphopenia affected mostly 
naïve and NSM B-cells, but again, with no evident 
association with disease activity status. Moreover, 
despite clear increase in the percentage of immature/ 
/early-transitional cells, there was no change in their 
absolute count. This observation confirms that bone 
marrow production of B-cells is not disturbed in 
SLE, as has been suggested previously [33]. Instead, 
our results support the concept on preferential de-
pletion of IgM+ memory pool in LN due to their 
constant activation (repeated exposure to self-an-
tigens) and continuous replenishing of SM-pool. 
However other explanations, e.g. abnormal selection 
processes or diminished susceptibility of particu-
lar memory B-cells to immunosuppressive drugs, 
are still possible. But autoreactive B-cells are only 
a tiny fraction of all memory cells, so why the whole 
compartment is changed? Some hints came from recent 
study, showing that various neutrophil-derived proin- 
flammatory mediators facilitate differentiation of IgD+ 
CD27+ memory B-cells and IgG class switch [10]. 
Neutrophils participate in the pathogenesis of LN, 
and both neutrophil derived cytokines (e.g. CCL2) 
and markers of neutrophil activation (extracellular 
traps) correlate with the activity of glomerulonephri-
tis and dsDNA titers [34, 35]. This implies that B-cell 
memory compartment in LN may also be shaped by 
innate immunity mediators released at the site of auto- 
immune inflammation. Because class switching and 
B-cell activation are under strict control of T-helper 
cells we further explored if similar changes of immune 
memory developed also in T-cell compartment. 
A characteristic feature of systemic autoimmun-
ity is constant exposure to tissue antigens, which 
favors differentiation of long-lasting TEM cells with 
well-developed effector functions [12]. In SLE this 
phenomenon may be associated with impaired immu-
nosuppression, due to persistently lower numbers of 
regulatory T-cells or their impaired function [36, 37]. 
Similarly to previous report [38], we observed low-
er frequency of naïve CD4+ T-cells and increased 
percentage of TEM fraction in both active- and inac-
tive-LN. Additionally, we showed that SLE-related 
lymphopenia affected mostly naïve CD4+ lympho-
cytes. The reasons for decreased CD4+ lymphocyte 
count in SLE are, however, poorly understood. It 
may result from higher susceptibility of T-cells to 
apoptosis due to diminished expression of comple-
ment regulatory proteins or defective Fas/Fas-ligand 
system [39]. The depletion of lymphocytes may also 
be linked with anti-lymphocyte antibodies, which are 
detected in ~50% of SLE patients presenting with 
lymphopenia [40]. Interestingly, we observed com-
parable decrease (~10-fold) in absolute counts of 
antigen inexperienced T-cells and NSM B-cells. We 
also showed a correlation between the percentage of 
naïve fractions of B-cells and CD4+ T-cells, as well as 
between their mature subsets. This observation sug-
gests that chronic antigenic stimulation and facilitated 
shift towards TEM may also contribute to lymphopenia 
in T-cell compartment. It is also tempting to speculate 
that decline in one compartment, e.g. in CD4+ T-cells, 
may trigger similar changes in the other. It has been 
shown that transient depletion of B cells can potently 
influence reactivation and maintenance of pathogen 
specific CD4+ T cells [40]. However, there are only 
scarce data on possible interaction between CD4+ 
lymphopenia and the concomitant quantitative chang-
es in B cell subsets [23, 42]. 
The presented data highlight similarities in chang-
es of B-cell and CD4+ T-cell subsets in LN patients, 
including deficiency in naïve (or non-switched) cells 
in all SLE patients and relative increase in effector 
memory (or exhausted) subsets during overt disease. 
LN-related changes in B-cell memory compartment, 
particularly the decline in NSM B-cells, may result 
from chronic antigenic stimulation and facilitated 
differentiation towards mature memory phenotypes, 
though it does not exclude possible intrinsic abnormal-
ities related to abnormal selection processes or vary-
ing sensitivity to immunosuppressants. Marked de-
crease in the percentage of circulating CD27+IgD+ 
memory B-cells was a typical signature of LN, while 
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the increase in CD21low B-cells could be used as addi-
tional laboratory marker of active disease. Whether 
B-cell memory subsets are skewed to the same extent 
in other SLE manifestations, or their diagnostic po-
tential in SLE remains to be further studied. 
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